Reopened USAntibiotics penicillin facility to relieve US dependence on Chinese antibiotics: Jackson Healthcare

The facility will be able to manufacture and stockpile a five-year supply of amoxicillin for the US

The plant, formerly owned by Neopharma, had slipped into bankruptcy and ceased operations in 2020 before being purchased by Jackson Healthcare earlier this year.

"As the first doses of USAntibiotics' life-saving drugs move down the assembly line, America will have declared its independence from Chinese antibiotics," said Rick Jackson, founder, CEO, and chairman of Jackson Healthcare. "Our mission is to solve our nation's reliance on foreign Amoxicillin and create a secure stockpile that will stand the test of time."

Upon reopening, USAntibiotics will be the only American company able to manufacture the popular antibiotics commonly known as Amoxil (amoxicillin) and Augmentin (amoxicillin clavulanate).

When the 360,000-sq. ft facility comes online, it will have the capacity to produce 300 million capsules and two billion tablets annually, meeting 100% of US amoxicillin demand, according to Jackson Healthcare.

Thirty percent of all antibiotics prescribed in the US each year are amoxicillin.

The facility can also manufacture and stockpile a five-year supply of amoxicillin for the US, a move that represents a complete reversal of the current situation whereby every dose is sourced from outside the US, primarily China, due to years of declining pharmaceutical production capacity in the US.

Earlier this year, US President Joe Biden ordered a review of crucial US supply chains, including pharmaceuticals.